Kornimate/medical-research-clean huggingface dataset:
srebf1 polymorphism and egg yolk on cardiovascular disease risk in healthy young adults: a randomised, two-period, single blinded, crossover trial

Conditions: Healthy; GEN1 Gene Mutation

Summary: our previous analysis showed that sterol regulatory element binding protein gene (srebf1) rs2236513/rs2297508/rs4925119 polymorphism modulated the relation between dietary cholesterol and serum low density lipoprotein cholesterol /serum total cholesterol. this study aims to confirm and extend this finding by characterizing the effects of cholesterol from egg yolks on lipid profiles in healthy young adults with different srebf1 genetic makeup. 32 srebf1 c/g/g minor allele carriers at rs2236513/rs2297508/rs4925119 and 32 srebf1 aa/cc/aa major homozygotes at rs2236513/rs2297508/rs4925119 were enrolled to test their response to egg yolks.


Eligibility criteria:
inclusion criteria: * srebf1 c/g/g minor allele carriers and aa/cc/aa major homozygotes at rs2236513/rs2297508/rs4925119, age 18-25 years, body mass index (bmi) 18\~23.9 kg/m2 , blood pressure within normal ranges (systolic blood pressure \ 1.04 mmol/l ), liver and kidney functions within normal ranges according to test kit instructions (alanine aminotransferase (alt) 9\~50 u/l for male, 7\~40 u/l for female; aspartate transaminase (ast) 15\~40 u/l for male, 13\~35 u/l for female; creatinine 62\~115 μmol/l for male, 53\~97 μmol/l for female; blood urea nitrogen (bun), 1.43\~7.14 mmol/l), both parents are chinese han nationality, willing to eat two or more eggs, and willing to maintain "three low diet" except when they were given egg yolks during the study. exclusion criteria: * history of diabetes, cancer, stroke, heart disease or any other known diseases, allergic to eggs, or having habits such as drinking or smoking.

Keywords: gene-by-diet interaction egg yolk sterol regulatory element binding protein 1 gene hdl-c ldl-c/hdl-c
international plastic bronchitis registry

Conditions: Plastic Bronchitis

Summary: the purpose of the international plastic bronchitis registry is to understand the natural course and long term health outcomes of subjects diagnosed with plastic bronchitis due to different types of casts. this provides essential data for identifying best practices and treatments. the secondary aim is to understand the structure of casts and mechanism of their formation.

plastic bronchitis (pb) patients have casts removed during bronchoscopy as part of their routine care or that they are able to expectorate (cough out) casts naturally. the casts are normally discarded. patients that agree to participate in the registry ship the airway casts and medical history to dr. bruce rubin's research laboratory at virginia commonwealth university richmond virginia, usa. the lab evaluates the biopolymer composition and structure of the airway casts by immunohistochemistry in order to identify microscopic differences between expectorated casts of subjects with plastic bronchitis and sputum from other populations (cystic fibrosis,chronic obstructive pulmonary disease , and normal airways). the lab also conducts in vitro evaluation of clearability, adhesivity, cohesivity, and inflammatory mediator concentrations to better understand the nature of the disease.

Eligibility criteria:
inclusion criteria: * diagnosed with plastic bronchitis

Keywords: plastic bronchitis pb
study of protein translocation in patients with beta-oxidation disorders

Conditions: Beta-Oxidation Disorder; Peroxisomal Disorders

Summary: objectives: i. characterize inheritance patterns of mutations in patients with beta-oxidation disorders.

protocol outline: patients undergo clinical and molecular analysis of beta-oxidation enzyme metabolism. the evaluation includes a urinary metabolite profile, and dna and familial studies.

Eligibility criteria:
protocol entry criteria: beta-oxidation disorder, including: medium-chain acyl-coenzyme a dehydrogenase deficiency long-chain 3-hydroxyacyl coenzyme a dehydrogenase deficiency very-long-chain acyl-coenzyme a dehydrogenase deficiency short-chain 3-hydroxyacyl coenzyme a dehydrogenase deficiency long-chain 3-ketoacyl-coenzyme a thiolase deficiency trifunctional protein deficiency patient age: 1 day and over

Keywords: beta-oxidation disorder inborn errors of metabolism rare disease
ultrasound-guided sciatic popliteal nerve block vs. erector spinae plane block in endovascular management of cli

Conditions: Critical Limb Ischemia (CLI); Popliteal Nerve Block; ESPB

Summary: comparison of popliteal sciatic nerve block and erector spinae plane block (espb) in patients undergoing endovascular management of critical lower limb ischemia (cli).

nerve blocks, particularly regional anesthesia techniques, have been increasingly used in the endovascular management of critical lower limb ischemia (cli). these techniques offer numerous advantages over general and local anesthesia. primary advantages of nerve blocks: 1. superior pain control nerve blocks, such as femoral and sciatic nerve blocks, provide effective pain relief by anesthetizing the nerve supply to the lower limb. they offer more comprehensive analgesia than local anesthesia alone, as they numb the entire area around the puncture site. 2. enhanced patient comfort nerve blocks allow patients to remain pain-free during and after the procedure. they minimize discomfort even in lengthy or complex cases. 3. reduction in systemic analgesic requirements by providing localized anesthesia, nerve blocks significantly reduce the need for systemic analgesics, particularly opioids. this is essential because cli patients often have comorbidities that make opioid use risky. 4. fewer opioid-related side effects nerve blocks reduce the incidence of opioid-related side effects, including nausea, vomiting, respiratory depression, and sedation. 5. improved hemodynamic stability nerve blocks preserve autonomic nervous system function, reducing fluctuations in blood pressure and heart rate compared to general anesthesia. this is especially beneficial for cli patients, who frequently have underlying cardiovascular disease.

Eligibility criteria:
inclusion criteria: 1. patient age will be 20-70 years. 2. patients will be diagnosed with critical lower limb ischemia by clinical presentations and investigations. 3. asa physical status 2-3 exclusion criteria: 1. patient refusal to participate in this study. 2. patient inability to understand the scales or to describe to the investigators. 3. coagulation disorder. 4. sever renal or kidney dysfunction. 5. taking opioids before admission. 6. morbid obesity .

Keywords: popliteal nerve block espb
effectiveness of cellutome epidermal harvesting system in autologous skin grafting of chronic wound patients

Conditions: Wounds and Injuries

Summary: this is multi-center prospective, longitudinal case series with comparison to historical controls.

the primary objective to this study is to determine the effectiveness of cellutome™ epidermal harvesting system as an outpatient skin grafting system for selected patients versus inpatient skin graft harvest. this is multi-center prospective, longitudinal case series with comparison to historical controls. in this study, all subjects will receive the same treatment protocol regardless of institution. this will include routine wound photography. ongoing healing process will be recorded and reviewed. the secondary objectives of this study are to establish an ideal donor site size, recipient site size and ideal patient population (especially high operative risk patients) that would benefit from the use of cellutome™ epidermal harvesting system.

Eligibility criteria:
inclusion criteria: * signed informed consent * patients requiring split-thickness skin grafting with non-infected wounds * age of participants: 18 years and above at the time of informed consent * gender: male or female * subjects who will be locally available for the next 6 months. exclusion criteria: * infected chronic wound * patients who are unable to adhere to scheduled study visits * patients who have severe arterial insufficiency requiring vascular intervention to restore adequate blood flow * patients who have an active drug/alcohol dependence or abuse history * use of investigational agents/devices on study or within 30 days prior to informed consent or within 30 days prior to use of device.
educational model for cardiac patients

Conditions: Coronary Artery Disease; Coronary Disease; Arteriosclerosis; Cardiovascular Diseases

Summary: the purpose of this study was to compare the effect of an educational model, which included cardiac rehabilitation with emphasis on physical activity and telephone follow up, with the usual management of individuals undergoing to first percutaneous coronary intervention, in relation to physical activity five until seven months after discharge.

randomized controlled trial (rct) at a public teaching hospital, which has specialized care for cad in ribeirão preto, state of são paulo, brazil. the intervention group received usual care and an educational programme and the control group received only usual care. a researcher (who didn't had contact with the patients) generated the random allocation in spss software, concealing it from the investigators in sequentially numbered, sealed and opaque envelopes. another researcher performed the individual interview with each participant (baseline) and aplied the instruments of socialdemographic data, physical activity, ansiety and depression, perceived health status and selfefficacy to practice of physical activity. at the end of the interviewthe same researcher opened the envelope to allocate the participants to either intervention or control group. the participants of intervention group remained with the researcher to receive the intervention. the educational programme consisted of four booklets entitled 1. percutaneous transluminal coronary angioplasty, 2. going home after your coronary angioplasty, 3. how to take care of your heart and your health, and 4. how to practice physical activities. the educational programme included the telephone follow-up that contained three calls to motivate the participants to change their lifestyle and clarify doubts. the contents of the booklets were explained step by step to the participants by the researcher who conducted the interviews.

Eligibility criteria:
inclusion criteria: * adult patients (18 years or more) of both genders * patients undergoing the first percutaneous coronary intervention * patients who had a properly functioning home phone line exclusion criteria: * no cognitive conditions to participate (assessed by the ability to inform the name, current date, day of the week, place, age and place of birth confirmed by the participant's identification document) * who did not have clinical or physical conditions to answer the questionnaires (individuals with dyspnea and / or mental confusion) * who reported difficulties to speak on the phone (hearing loss) * who had sequelae that could influence activities of daily living (limb amputation or paralysis) * who had a contraindication to physical exercise, prescribed by the doctor, and who already participated in a supervised cardiac rehabilitation program
manuka honey eye drops vs conventional treatment of meibomian gland dysfunction related dry eye disease

Conditions: Meibomian Gland Dysfunction

Summary: assessor-masked (single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% manuka honey topical eye drops.

purpose to evaluate the effects of conventional treatment compared to use of manuka honey eye drops in the treatment of meibomian gland dysfunction related dry eye disease. design assessor-masked (single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% manuka honey topical eye drops. methods patients were randomized into two groups, one group given conventional treatment for meibomian gland dysfunction. the other group was given additional manuka honey 16% eye drops which are registered as a medical device by the australian fda. speed score was taken at baseline and upon follow up. multiple parameters were graded from slit lamp examination by a masked assessor. results were compared from baseline to follow up date 3 weeks later.

Eligibility criteria:
inclusion criteria: * meibomian gland dysfunction stage 2-4 exclusion criteria: * \<18 years old unable to consent recent ophthalmic surgery \<6m abnormalities of lid position allergy to honey/bee products contact lens wearers patients on long term topical medications apart from lubricants
a phase ii study of anlotinib in sts patients

Conditions: Cancer

Summary: anlotibib (altn) is a kind of innovative medicines approved by state food and drug administration（sfda） which was researched by jiangsu chia-tai tianqing pharmaceutical co., ltd. altn is a kinase inhibitor of receptor tyrosine with multi-targets, especially for vegfr2 and vegfr3. it has the obvious resistance to new angiogenesis. the protocol is to explore altn for the effectiveness of advanced soft tissue sarcoma and security.


Eligibility criteria:
inclusion criteria: * 1.faild in introditional treatmeat, mainly includes:mfh/liposarcoma/leiomyosarcoma/ss and others(mpnst/fibrosarcoma/ccs/asps/as/es; 2.receiveed at least one chemotherapy regimens treatment; 3.18-70years, ecog:0-2,expected survival period \>3 months; 4.hb≥100g/l,anc(absolute neutrophil count) ≥1.5×109/l；plt * 80×109/l ,bil/cr in normal range,alt/ast(aspartate aminotransferase )≤1.5\*uln(for hepatic metastases,alt/ast(aspartate aminotransferase )≤5\*uln) ;tg≤ 3.0mmol/l，cholesterol≤7.75mmol/l; lvef * lln. 5.used contraceptive during the study and after 6 months; 6.volunteer. exclusion criteria: * 1. received vascular endothelial growth inhibitor type of targeted therapy; 2.with the second cancer; 3.participated in other clinical trials in four weeks; 4.received in other radiotherapy or chemotherapy treatment in four weeks; 5.ae\>1 6.has influence of oral drugs; 7.brain metastases, spinal cord compression, cancerous meningitis; 8.any serious or failed to control the disease 9.artery/venous thrombotic; 10.coagulant function abnormality; 11.arteriovenous thrombosis event; 12.hitory of psychiatric drugs abuse or a mental disorder; 13.immunodeficiency history; 14.concomitant diseases.
improving identification of mental health/substance use disorders in hiv primary care: pilot clinical response

Conditions: HIV Infections

Summary: this research is a feasibility pilot of an intervention to respond to positive screening tests for mental health(mh) and substance use (su) captured through the patient reported outcomes questionnaires (pros). the pros are currently performed in the clinic, however, the results are neither reviewed with patients nor transmitted to providers. this pilot assesses the feasibility of moving the pros into the clinical realm by having patients review the pro results, identifying an issue to discuss at the patient's next hiv primary care visit, and determining whether this process increases discussion of mh and su disorders in the subsequent clinical visit and/or increases referrals to mh and/or su treatment.


Eligibility criteria:
inclusion criteria: * must be enrolled in the johns hopkins clinical cohort at the johns hopkins moore clinic * must be living with hiv exclusion criteria: -
pharmacokinetics and clinical response of tolvaptan in neurocritical care patients

Conditions: Brain Injury; Hyponatremia

Summary: to assess the pharmacokinetic profile of tolvaptan in critically ill acute brain injury patients and to secondarily evaluate the clinical response and safety of tolvaptan in acute brain injured patients


Eligibility criteria:
inclusion criteria: 1. acute brain injury patients in the icu with hyponatremia (na \< 135 mmol/l) necessitating treatment in addition to fluid restriction per clinical judgement or patients at risk for worsening cerebral edema 2. informed consent obtained from patient or authorized legal representative 3. age ≥ 18 years exclusion criteria: 1. use of cyp3a4 inhibitors or inducers as medications, juices, or herbal supplements within 96 hours prior to the study period. 2. a positive urine or serum pregnancy test, or are currently breast-feeding 3. patients with subarachnoid hemorrhage or in patients suspected to have cerebral salt wasting or any signs of volume depletion 4. imminent death or brain death 5. concomitant fungal infection 6. history of hiv 7. concomitant administration of continuous infusion hypertonic saline, conivaptan or hypertonic saline bolus within 24 hours of study drug administration 8. diuretic or mannitol administration within 6 hours 9. serum creatinine ≥ 3.5 mg/dl 10. diagnosis of cirrhosis or liver function tests \> 2x the upper limit of normal
s0224, docetaxel in treating patients with locally advanced or metastatic penile cancer (terminated)

Conditions: Penile Cancer

Summary: rationale: drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of docetaxel in treating patients who have locally advanced or metastatic penile cancer.

objectives: * determine the confirmed complete and partial response rate in patients with locally advanced or metastatic epidermoid carcinoma of the penis treated with docetaxel. * determine the progression-free and overall survival of patients treated with this drug. * determine the qualitative and quantitative toxic effects of this drug in these patients. outline: patients receive docetaxel iv over 15-30 minutes on days 1, 8, and 15. treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 1 year and then every 6 months for 2 years. projected accrual: a total of 20-40 patients will be accrued for this study within 3-5.8 years.

Eligibility criteria:
disease characteristics: * histologically confirmed epidermoid carcinoma of the penis * distant metastases (m1) or * pathologically confirmed regional nodal metastases (n1-3) * measurable disease * soft tissue disease irradiated within the past 2 months is not considered measurable disease patient characteristics: age * not specified performance status * zubrod 0-2 life expectancy * not specified hematopoietic * white blood cell (wbc) count at least 3,000/mm\^3 * absolute granulocyte count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic * bilirubin no greater than upper limit of normal (uln) * aspartate aminotransferase (sgot) no greater than 2.5 times uln * if sgot is greater than uln, alkaline phosphatase must be no greater than 2.5 times uln * alkaline phosphatase no greater than 4 times uln * if alkaline phosphatase is greater than uln, sgot must be no greater than 1.5 times uln renal * not specified other * fertile patients must use effective contraception * no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage i or ii cancer currently in complete remission * no grade 2 or greater peripheral neuropathy * no hypersensitivity to drugs formulated with polysorbate 80 (e.g., recombinant interferon alfa-2a, multivitamin infusion, etoposide, infliximab, or novoseven factor) prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior chemotherapy for penile cancer endocrine therapy * not specified radiotherapy * see disease characteristics * at least 28 days since prior radiotherapy and recovered surgery * not specified

Keywords: stage ii penile cancer stage iii penile cancer stage iv penile cancer
intravenous (iv) methylnaltrexone (mntx) in the prevention of post-operative ileus

Conditions: Postoperative Ileus

Summary: a double-blind, randomized, parallel-group study designed to evaluate the safety and activity of iv mntx in the treatment of post-operative ileus (poi) in patients who underwent segmental colectomies via laparotomy.


Eligibility criteria:
inclusion criteria: 1. males and females, 18 yrs or older 2. patients who have undergone a segmental colectomy 3. must be receiving opioids via iv. exclusion criteria: 1. patients who received any experimental drug in the last 30 days 2. patients receiving spinal medication for post-operative pain relief 3. patients who have undergone operations for complications related to inflammatory bowel disease 4. patients with recent history of abdominal radiation therapy.
cold application in lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: purpose: the purpose of this study was to investigate which cold application is more effective to regulate skin temperature in patients with lateral epicondylitis. materials and methods: fifty-four patients with lateral epicondylitis were randomly divided into 2 groups as cooling gel (n=27) group and cold pack (n=27) group. cooling gel and cold pack applications were applied on painful lateral epicondyle region for 15 minutes. patients were assessed before and after the application. assessments included the severity of pain during wrist extension, evaluated by visual analog scale (vas) and thermal imaging of lateral epicondyle region evaluated by infrared thermography (flir5 thermal camera).


Eligibility criteria:
inclusion criteria: * subjects with elbow pain for at least 3 months * those between 20 and 40 years of age * who did not have cold allergies exclusion criteria: * with a different elbow problem or multiple elbow problems, * having cervical or other upper extremity problems, * elbow joint operation, * tendon rupture, * limited range of motion due to humerus, radius or ulna fracture * individuals with a history of osteoporosis, malignancy, hemophilia, neurological effect, and cognitive dysfunction

Keywords: kinesio tape thermal analysis cold